TLA Targeted Immunotherapies AB (TLA) is a biotech spinout company developed at the Karolinska Institute and Karolinska University Hospital.

The company’s interdisciplinary team of scientists, entrepreneurs, and industrial leaders is working closely with immunological research groups at Karolinska to develop novel medical devices designed to combat Immune Mediated Inflammatory Diseases (IMIDs).

Following proof of concept of its Tailored Leukapheresis (TLA™) treatment for Inflammatory Bowel Disease, and after seeking systematic market-feedback from commercial partners and regulators, the company is currently conducting the final clinical studies before commercialization.

Funding


TLA technology has been developed with approximately SEK 150 million (EUR 15 million) in R&D funding:

In addition to a total shareholders’ contribution and licensing revenues of approximately SEK 100 million, TLA™ technology has received funding from the following sources based on competitive research:

2012: European Union (Phase I/II Clinical Trial on ARDS): SEK 5 Million.

2012: Universal Biotech Innovation Prize: EUR 50 000

2013: Swedish Research Council (Phase I/II Clinical Trial on pediatric IBD, PSC, alcoholic hepatitis, RA, MS and ALS): SEK 5 Million.

2013: Swedish Governmental Agency for Innovation Systems (Phase II Clinical Trial on IBD): SEK 5 Million.

2018: European Union Horizon 2020 (Head to Head Clinical Study with TNF-a): EUR 2.7 million. TLA is currently setting up a head to head clinical study comparing selective aphaeresis using TLA Gut vs TNFa blocker. The study is divided in two parts. The first part is a short safety study conducted in Sweden with 12 patients. The second part will include 160 patients over several European countries. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 812021
EU flag

2010:

Swedish Governmental Agency for Innovation Systems (Phase I/II Clinical Trial on IBD): SEK 5 Million.

2012:

European Union (Phase I/II Clinical Trial on ARDS): SEK 5 Million.

2012:

Universal Biotech Innovation Prize: EUR 50 000

2013:

Swedish Research Council (Phase I/II Clinical Trial on pediatric IBD, PSC, alcoholic hepatitis, RA, MS and ALS): SEK 5 Million.

2013:

Swedish Governmental Agency for Innovation Systems (Phase II Clinical Trial on IBD): SEK 5 Million.

2018:

European Union Horizon 2020 (Head to Head Clinical Study with TNF-a): EUR 2.7 million.

TLA is currently setting up a head to head clinical study comparing selective aphaeresis using TLA Gut vs TNFa blocker. The study is divided in two parts. The first part is a short safety study conducted in Sweden with 12 patients. The second part will include 160 patients over several European countries. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 812021

EU flag

Market

Inflammatory Bowel Disease Market

  • Total Addressable Market (TAM) is projected to reach USD 7,644 Million in 2020 at CAGR of 6.1%. Biologics dominate the market (68%).
  • The number of patients at market entry is estimated at > 2.3 million individuals.
  • There is an obviously – and currently unpenetrated – market space for non-pharmaceutical based IBD therapies that combine cost-efficiency with high efficacy and a personalized medicine approach. This low-competition niche constitute the targeted space to be occupied by TLA.

Competitive Profile

The competitive landscape for TLA in IBD is composed of drug therapies (primarily immunomodulatory and TNF-a inhibitors), and non-specific leukapheresis columns.

  • In contract to these systemic drugs, TLA has an attractive, clinically proven, safety and efficacy profile making its suitable even for long-term use.
  • TLA is clearly advantageous to currently available apheresis columns being a specific, high-efficacy therapy that requires only 1 column / year for maintenance treatment.

IMIDs

Immune Mediated Inflammatory Diseases (IMIDs) include approximately 80 diseases, which are all caused and maintained by an exaggerated inflammatory response triggered by an imbalance of the immune system. IMIDs affect approximately 10% of the global population with a variety of high prevalence, rare, and untreatable diseases that have a combined socioeconomic impact comparable to that of infectious diseases or cancer.

Since many IMIDs are difficult to treat without debilitating and severe side effects – or cannot be treated at all – there remains a large medical need and market opportunity.

Market Size

The Global Immune Mediated Inflammatory Disease Treatment Market is expected to grow steadily from USD 100.4 Billion in 2017 to USD 153.5 Billion in 2024, at a moderate CAGR of 6.3% from 2018 to 2024.

Team

Hans Glise

Chairman

Hans Glise

Chairman

Hans Glise MD, PhD has a professorship in surgery, vast experience of clinical research both from the clinical side and as Head of Clinical research in several Therapy Areas in Astra Zeneca, Novo Nordisk and UCB. Dr Glise also was the drivning force behind the creation of SCUR, a clinical research group of 30 clinics in medicine and Surgery in Sweden, Norway and Finland.

Ahsan Amjad

Managing Director & CEO

Ahsan Amjad

Managing Director & CEO

Ola Winqvist

Chief Scientific Officer

Ola Winqvist

Chief Scientific Officer

Ludvig Linton

Chief Technical Officer

Ludvig Linton

Chief Technical Officer

Martin Hyllienmark

Chief Operating Officer

Martin Hyllienmark

Chief Operating Officer

Martin holds a double B.Sc degree from Stockholm University and University of Greenwich, UK. Martin has been working with TLA since 2015.

Augusta Broomé

QA/RA Manager

Augusta Broomé

QA/RA Manager

Augusta holds a Master of Science from Uppsala University. During her career Augusta has focused on specializing in immunology and the QA/RA field.

Catharina Johansson

Project Leader

Catharina Johansson

Project Leader

Catharina holds a PhD in Immunology from the Karolinska Institutet. Catharina has more than 30 years experience of immunological research at Karolinska Institutet, Uppsala University and AstraZeneca.

Stefan Warin

Board Member and Advisor

Stefan Warin

Board Member and Advisor

Jonas Winqvist

Board Member

Jonas Winqvist

Board Member

.

Contact

TLA Targeted Immunotherapies AB
Nanna Svartz Väg 2
171 65 Solna
Sweden

martin.hyllienmark@tlatherapies.com

Google map